Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects-Reference-Cited by-同舟云学术

Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects

Published:2017-04 Issue: Volume:155 Page:43-55
ISSN:0091-3057
Container-title:Pharmacology Biochemistry and Behavior
language:en
Short-container-title:Pharmacology Biochemistry and Behavior

Author:

Witkin JM,Monn JA,Li J,Johnson B,McKinzie DL,Wang X-S,Heinz BA,Li R,Ornstein PL,Smith SC,Mitch CH,Calligaro DO,Swanson S,Allen D,Phillips K,Gilmour G

Publisher

Elsevier BV

Subject

Behavioral Neuroscience,Biological Psychiatry,Clinical Biochemistry,Pharmacology,Toxicology,Biochemistry

Reference34 articles.

1. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics;Abdallah;Annu. Rev. Med.,2015

2. A role for AMPA receptors in mood disorders;Alt;Biochem. Pharmacol.,2006

3. Antidepressant effects of ketamine in depressed patients;Berman;Biol. Psychiatry,2000

4. MGS0039: A Potent and Selective Group II Metabotropic Glutamate Receptor Antagonist With Antidepressant-like Activity;Chaki,2004

5. Discovery of LY3020371, a potent and selective orthosteric antagonist of mGlu2/3 receptors;Chappell;J. Med. Chem.,2016

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development;European Archives of Psychiatry and Clinical Neuroscience;2023-01-30

2. Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms;General Psychiatry;2022-12

3. Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?;Cellular and Molecular Neurobiology;2022-11-29

4. Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders;Pharmacology Biochemistry and Behavior;2022-11

5. Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram;Pharmacology Biochemistry and Behavior;2022-01